rimacalib

a CaMKII inhibitor with therapeutic potential for the treatment of rheumatoid arthritis and arrhythmia

Also Known As:

N'-(3-((1S)-1-(2-fluoro-4-biphenylyl)ethyl)-1,2-oxazol-5-yl)-4-morpholinecarboximidamide; SMP-114

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

1.	Dybkova, Nataliya: 1 article (01/2017)
2.	Maier, Lars S: 1 article (01/2017)
3.	Mann, Christian: 1 article (01/2017)
4.	Neef, Stefan: 1 article (01/2017)
5.	Zwenger, Anne: 1 article (01/2017)
6.	Bouwman, Erwin: 1 article (09/2009)
7.	Brouwer, Elisabeth: 1 article (09/2009)
8.	Doornbos-van der Meer, Berber: 1 article (09/2009)
9.	Kallenberg, Cees G M: 1 article (09/2009)
10.	Limburg, Pieter C: 1 article (09/2009)

1.	Experimental Arthritis 09/01/2009 - "The present study was designed to investigate the effects of a novel CaMKII inhibitor SMP-114, which was effective in a collagen-induced arthritis model in rats, on rheumatoid synovial fibroblasts. "
2.	Rheumatoid Arthritis 01/01/2017 - "SMP-114 ("Rimacalib") is a novel, orally available CaMKII inhibitor developed for human use that has already entered clinical phase II trials to treat rheumatoid arthritis. "
3.	Heart Failure 01/01/2017 - "SMP-114 demonstrated potential to treat SR Ca2+ leak and consequently proarrhythmogenic events in rodent as well as in human atrial cardiomyocytes and cardiomyocytes from patients with heart failure. "

1.	Calcium-Calmodulin-Dependent Protein Kinase Type 2
2.	rimacalib